Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: Evidence of enhanced in vitro activity

Diagnostic Microbiology and Infectious Disease

Volumn 47, Issue 2, 2003, Pages 415-419

  Kontoyiannis, Dimitrios P ^a,b   Lewis, Russell E ^a,b   Lionakis, Michail S ^a   Albert, Nathaniel D ^a   May, Gregory S ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

A. fumigatus; Caspofungin; ; Itraconazole;

Indexed keywords

CASPOFUNGIN; ITRACONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC;

EID: 1642345522     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00136-6     Document Type: Article

References (12)

1. Bammert G.F., Fostel J.M. Genome-wide expression patterns in Saccharomyces cerevisiae comparison of drug treatments and genetic alterations affecting biosynthesis of ergostetrol. Antimicrob Agents Chemother. 44:2000;1225-1263.
2. Bowman J.C., Hicks P.S., Kurtz M.B., Rosen H., Schmatz D.M., Liberator P., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 46:2002;3001-3012.
3. De Backer M.D., Ilyina T., Ma X.J., Vandoninck S., Luyten W.H., Vanden Bossche H. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother. 45:2001;1660-1670.
4. Groll A.H., Piscitelli S.C., Walsh T.H. Clinical pharmacology of systemic antifungal agents A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 44:1998;343-500.
5. Harousseau J.L., Dekker A.W., Stamatoulas-Bastard A., Fassas A., Linkesch W., Gouveia J., et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole to amphotericin B. Antimicrob Agents Chemother. 44:2000;1887-1893.
6. Kontoyiannis D.P. Genetic analysis of azole resistance by transposon mutagenesis in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 43:1999;2731-2735.
7. Kontoyiannis D.P., Bodey G.P. Invasive aspergillosis in 2002 An update. Eur J Clin Microbiol Infect Dis. 21:2002;161-172.
8. Kontoyiannis D.P., Lewis R.E., Sagar N., May G., Prince R.A., Rolston K.V. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus an E-test-based strategy. Antimicrob Agents Chemother. 44:2000;2915-2918.
9. Lewis R.E., Prince R.A., Kontoyiannis D.P. Pretreatment with itraconazole attenuates the efficacy of increasing amphotericin B dosages in a murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 46:2002;3208-3214.
10. Maertens, J., Raad, I. I., Petrikkos, D., Selleslag, D., Petersen, F., Sable,C., Kartsonis, N., Ngai, A., Taylor, A., Patterson, T., Denning, D., Walsh, T. (2002). Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive Aspergillus (IA) refractory or intolerant to other antifungal agents: Analysis of 90 patients. 42nd Interscience Con-ference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, CA. Abstract 388:M-868
11. Pfaller M., Riley J. Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida. Eur J Clin Microbiol Infect Dis. 11:1992;152-156.
12. Van Burik, J., Ratanatharathorn, V., Lipton, J., Miller, C., Bunin, N., Walsh, T. J. (2002). Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002